| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6414cf0912e2737a41f574e3435772e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b015ca2b2715b74db5868852efe71c9d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d735978d779cddcf9e226c7c3a52e542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eec86be9900aae40f14044a3d42627cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dfa2dbaacf9632e19d2cd8d188eec28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1b04b8a88b5adbcb203cd68dc5e6012 |
| publicationDate |
2021-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202130349-A |
| titleOfInvention |
Use of pd-1 antibodies in combination with paclitaxel compounds in the preparation of drugs for the treatment of triple-negative breast cancer |
| abstract |
The disclosure relates to the use of PD-1 antibodies in combination with paclitaxel compounds in the preparation of drugs for the treatment of triple-negative breast cancer. Specifically, the use of PD-1 antibodies in combination with a molecular chemotherapeutic agent such as paclitaxel in the preparation of drugs for the treatment of triple-negative breast cancer is provided, and the combination therapeutic regimen exhibits superior disease control and objective response rates, embodies the synergistic effect of the combination drug, and significantly improves the efficacy of immunotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023040804-A1 |
| priorityDate |
2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |